• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Activin E Loss May Improve Fat Distribution but Raise Hepatic Lipid Risks

by
November 17, 2026
in Health
Reading Time: 5 mins read
0
Activin E Loss May Improve Fat Distribution but Raise Hepatic Lipid Risks

Activin E Loss May Improve Fat Distribution but Raise Hepatic Lipid Risks

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A narrative review published in Frontiers in Endocrinology examines how the liver-derived hormone activin E and its primary receptor ALK7 regulate adipose tissue lipolysis, body fat distribution, and systemic insulin resistance. Researchers Zhuoshi Yang, Na Zhao, and Jian Ma from the First Affiliated Hospital of Heilongjiang University of Chinese Medicine synthesized human exome-sequencing discoveries alongside preclinical rodent and cell-culture experiments to evaluate whether targeting this signaling pathway represents a viable metabolic intervention. In human genetic studies, lifelong partial loss-of-function variants in the activin E gene INHBE correlate with a favorable waist-to-hip ratio and reduced diabetes susceptibility. However, the authors emphasize that experimental ablation of the pathway in animal models frequently diverts unesterified lipid flux directly into hepatic tissue, provoking steatohepatitis and metabolic dysfunction.

Insulin resistance serves as a primary pathogenic driver across type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and atherosclerotic cardiovascular disease. In healthy metabolic regulation, circulating insulin promotes peripheral glucose uptake in skeletal muscle and adipose tissue while suppressing endogenous glucose production in hepatocytes. When peripheral tissues become refractory to physiological insulin concentrations, compensatory pancreatic beta-cell insulin secretion temporarily maintains glycemic control until eventual secretory failure leads to overt hyperglycemia. The capacity of subcutaneous adipose tissue to store surplus energy functions as a buffer against lipotoxicity; when expandability is genetically constrained or overwhelmed by nutrient excess, circulating lipids accumulate ectopically within non-adipose organs such as the liver and skeletal muscle, disrupting canonical intracellular signaling cascades.

The hepatokine activin E is encoded by the INHBE gene, which translates into a 350-amino-acid precursor protein within the transforming growth factor-beta superfamily. The polypeptide architecture includes an amino-terminal signal peptide spanning residues 1 to 19, an extensive prodomain across positions 20 to 236, and a mature beta-E chain between residues 237 and 350. Mature monomers assemble through intermolecular disulfide bonds into homodimers that are secreted primarily by hepatocytes into the systemic circulation. Hepatocytes upregulate INHBE expression in response to non-esterified fatty-acid exposure and acute cellular stress. Transcriptional profiling reveals that endoplasmic reticulum stress induces hepatic INHBE transcription through activating transcription factor 4, while insulin-stimulated promoter activity depends on CCAAT/enhancer-binding proteins, positioning activin E as an endocrine communicator of hepatic lipid load.

Upon secretion, circulating homodimeric activin E targets the type I serine/threonine kinase receptor ALK7, encoded by ACVR1C, which exhibits concentrated expression in adipose depots. Signal transduction requires activin E to engage cell-surface receptor complexes containing the shared type II receptors ActRIIA or ActRIIB before recruiting and phosphorylating ALK7. The activated receptor complex phosphorylates intracellular SMAD2 and SMAD3 proteins, which assemble with SMAD4 and translocate into the nucleus to modulate target gene transcription. Unlike activin A, mature activin E displays biochemical resistance to neutralization by extracellular endogenous antagonists such as follistatin and WFIKKN. In mature adipocytes, SMAD2/3 activation downregulates key adipogenic and lipolytic transcription factors, including peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding protein alpha, suppressing adipose triglyceride lipase expression and beta-3 adrenergic receptor signaling.

This ligand-receptor cascade operates as an endocrine negative-feedback loop coordinating inter-organ lipid handling. During sustained fasting or adrenergic stimulation, accelerated adipocyte lipolysis releases non-esterified fatty acids into the bloodstream, elevating hepatic fatty-acid exposure and triggering Inhbe transcription in hepatocytes. Secreted activin E then travels to adipose depots, binding ALK7 complexes to dampen cyclic adenosine monophosphate and protein kinase A signaling, thereby blunting catecholamine responsiveness and checking excessive fat mobilization. While this physiological brake preserves critical lipid stores during extended starvation, persistent hepatic overexpression during chronic nutrient overload drives pathological adipocyte hypertrophy, lipid retention, and catecholamine resistance. Because ALK7 also accepts inputs from alternative ligands including activin B, activin C, and GDF3, receptor-level interventions reflect composite regulatory inputs rather than ligand-specific activin E signaling.

Independent large-scale human genetic studies provide foundational evidence linking the pathway to metabolic phenotypes. Exome-sequencing analyses by Deaton and colleagues encompassing 362,679 individuals revealed that heterozygous predicted loss-of-function variants in INHBE associate with significantly lower body mass index-adjusted waist-to-hip ratios. An in vitro functional assessment demonstrated that a common in-frame deletion variant decreased secreted protein by approximately 90 percent. Corroborating these findings, a multi-ancestry exome investigation by Akbari and colleagues evaluating 618,375 participants confirmed that heterozygous INHBE protein-truncating variants associate with favorable adipose distribution, more favorable lipid profiles, and an estimated 28 percent reduction in type 2 diabetes odds, showing that rare coding variants in adipose pathways exert substantial phenotypic effects.

Complementary genetic evidence emerges from the receptor level, where coding mutations in ACVR1C mirror the protective anthropometric signatures of INHBE disruption. In an analysis of 405,569 UK Biobank participants, Emdin and coworkers identified four ACVR1C variants associated with reduced body mass index-adjusted waist-to-hip ratios: Asn150His, Ile195Thr, Ile482Val, and the noncoding allele rs72927479. Dual-energy X-ray absorptiometry confirmed lower abdominal fat percentages among carriers, and each genetically predicted 0.2 standard-deviation reduction in waist-to-hip ratio correlated with a 30 percent reduction in type 2 diabetes odds. However, knock-in mouse models carrying the human Ile195Thr missense substitution caution against straightforward extrapolation: when challenged with a high-fat diet, homozygous Ile195Thr rodents exhibited reduced adiposity accompanied by elevated fasting insulin, impaired insulin tolerance, and pronounced hepatic steatosis.

Preclinical gene-knockout studies underscore a critical physiological trade-off between reducing peripheral adipose mass and exacerbating hepatic lipotoxicity. In constitutive Inhbe-knockout mice subjected to high-fat diets, absolute white adipose tissue volume and adipocyte diameters decrease, but circulating non-esterified fatty acids rise substantially. Griffin, Adam, and Sakaki observed that unconstrained lipolysis directs massive fatty-acid flux to the liver, exceeding hepatic oxidative and export capacities. In male constitutive knockout mice, complete Inhbe deficiency produced hepatomegaly, severe triglyceride accumulation, ballooning degeneration, and hepatic fibrosis matching a lean steatohepatitis phenotype alongside systemic insulin resistance. In female knockout rodents, overt liver pathology manifested later, yet insulin tolerance was impaired prior to advanced histological damage, highlighting significant sex-dependent timelines in metabolic progression.

Experimental attempts to modulate the pathway pharmacologically yield divergent metabolic outcomes that vary by modality, duration, and target specificity. Short-term administration of Inhbe-targeting small interfering RNA in obese db/db mice suppressed weight gain, decreased fat volume, lowered the respiratory quotient, and elevated circulating ketones over 14 days, indicating increased whole-body lipid utilization, yet oral glucose tolerance remained unchanged and long-term liver outcomes were not reported. Conversely, systemic ALK7-neutralizing antibodies tested over extended intervals in obese mice improved glycemic profiles and systemic insulin action, with early elevations in hepatic triglycerides attenuating over time. Furthermore, broad ActRIIA and ActRIIB blockade increased skeletal muscle mass but triggered cardiac glycogen deposition, myocardial hypertrophy, and deteriorated glucose tolerance, proving that shared receptor interventions carry off-target systemic liabilities.

Translational initiatives have advanced into early human trials, including clinical evaluations of the INHBE-targeting oligonucleotide WVE-007 and the ACVR1C-directed RNA interference candidate ARO-ALK7 listed on ClinicalTrials.gov. The review authors stress that while human genetics validates target prioritization, lifelong heterozygous gene deficiency cannot predict adult pharmacological parameters, optimal dosing windows, or tissue-specific reversibility. Whether therapeutic agents utilizing liver-targeted GalNAc conjugates or adipose-directed delivery can achieve a moderate, reversible suppression of activin E signaling that improves body fat distribution without instigating steatohepatitis remains an unresolved clinical question. Future human investigations must concurrently monitor hepatic lipid fractions, non-esterified fatty-acid kinetics, insulin clamp dynamics, and histological markers of hepatic inflammation to define a safe therapeutic boundary.

Subject of Research: Endocrine regulation of body fat distribution, adipose lipolysis, and insulin resistance by the activin E and ALK7 signaling axis

Article Title: Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives

Article References: Yang, Z., Zhao, N., & Ma, J. (2026). Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives. Frontiers in Endocrinology, 17, Article 2005408. https://doi.org/10.3389/fendo.2026.2005408

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.2005408

Keywords: activin E, INHBE, ALK7, ACVR1C, insulin resistance, adipose lipolysis, body fat distribution, steatohepatitis, hepatokines, type 2 diabetes, SMAD2/3 signaling, PPARgamma, non-esterified fatty acids, exome sequencing, metabolic endocrinology, hepatic lipid burden, ActRIIB

News Source: Ophelia Keating. (November 17, 2026). Activin E Loss May Improve Fat Distribution but Raise Hepatic Lipid Risks. Scienmag.

Tags: activin EActRIIBACVR1Cadipose lipolysisALK7body fat distributionexome sequencinghepatic lipid burdenhepatokinesINHBEinsulin resistancemetabolic endocrinologynon-esterified fatty acidsPPARgammaSmad2/3 signalingsteatohepatitisType 2 diabetes
Share12Tweet7Share2ShareShareShare1

Related Posts

Overweight Adults at High Altitude Face Higher Fatty Liver Disease Risk

Overweight Adults at High Altitude Face Higher Fatty Liver Disease Risk

November 17, 2026
Review Reveals Dual Tumor Promoting and Suppressive Functions of Cytoskeletal MYH9

Review Reveals Dual Tumor Promoting and Suppressive Functions of Cytoskeletal MYH9

November 17, 2026

Accelerated Biological Aging Predicts Poor Prognosis Following Acute Ischemic Stroke Therapy

November 17, 2026

Case Report Details Cardiac Asystole During Balloon Dilation in Retroperitoneal Laparoscopic Nephrectomy

November 17, 2026

POPULAR NEWS

  • High Prevalence of Gender-Based Violence Follows Armed Conflict in Southern Tigray

    High Prevalence of Gender-Based Violence Follows Armed Conflict in Southern Tigray

    29 shares
    Share 12 Tweet 7
  • Air Pollutants Tied to Adverse Sleep Outcomes Amid Notable Evidence Uncertainty

    29 shares
    Share 12 Tweet 7
  • Network Analysis Identifies Core Positive Development Attributes in Rural Chinese Adolescents

    29 shares
    Share 12 Tweet 7
  • China Silver Economy Policies Show Good Overall Consistency but Uneven Regional Breadth

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Immune and Proliferative Gene Signatures Predict Brain Tumor Mortality Across Both Sexes

Hydrothermal Synthesis Pairs Carbon Nitride with Molybdenum Disulfide for Water Splitting

Overweight Adults at High Altitude Face Higher Fatty Liver Disease Risk

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.